Crohn’s/IBD - Medical-Marijuana

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your treatment plan. Medical marijuana laws vary by state — verify the rules in your jurisdiction before proceeding.

Introduction

Crohn’s disease is one of the most debilitating chronic conditions a person can live with. It is unpredictable, often treatment-resistant, and its symptoms — severe abdominal pain, chronic diarrhoea, debilitating fatigue, weight loss, and the constant threat of a flare — can make normal daily life feel impossible. For the estimated 1 to 1.5 million Americans living with Crohn’s disease, finding relief is a continuous, exhausting pursuit.

Medical cannabis has emerged as a treatment option of genuine interest to the gastroenterology community and to patients who have found conventional therapies inadequate. The endocannabinoid system (ECS) is now well-established as a key regulator of gastrointestinal function, intestinal inflammation, and gut-brain signalling — placing it directly in the pathophysiological pathway of Crohn’s disease. Clinical trials, real-world registry data, and a growing body of systematic reviews suggest that cannabis may help patients manage pain, reduce symptom burden, and in some cases induce clinical remission.

This article explains what Crohn’s disease is, how the ECS is uniquely relevant to gut inflammation, what the clinical evidence shows, which cannabinoids are most studied, and how Crohn’s patients can legally access medical marijuana in the United States.

What Is Crohn’s Disease?

Crohn’s disease is a chronic inflammatory bowel disease (IBD) characterised by transmural (full-thickness) inflammation that can affect any part of the gastrointestinal (GI) tract — from the mouth to the anus. Unlike ulcerative colitis, which is limited to the colon and rectum, Crohn’s disease can involve any segment of the digestive tract, most commonly the terminal ileum (the end of the small intestine) and the colon.

The disease is characterised by a relapsing-remitting course — cycles of active inflammation (flares) alternating with periods of remission. For many patients, remission is partial or short-lived, and achieving and maintaining deep remission — both clinical and endoscopic — is the central challenge of long-term Crohn’s management.

Core symptoms

Abdominal pain and cramping — often severe, typically in the lower right abdomen
Chronic diarrhoea — frequently urgent and sometimes bloody
Fatigue — often described as the most disabling non-pain symptom
Unintentional weight loss and malnutrition — due to malabsorption and reduced food intake from pain
Nausea and vomiting
Fever — during active flares
Perianal disease — fistulas, abscesses, and skin tags in a significant proportion of patients
Extraintestinal manifestations — joint pain, skin lesions (erythema nodosum, pyoderma gangrenosum), eye inflammation, and liver complications affect a substantial minority

Who it affects

A 2023 cross-sectional retrospective study of more than 14 million people in the United States estimated that approximately 1.01 million Americans have Crohn’s disease, with a prevalence of approximately 305 cases per 100,000 people.
More recent estimates place the total diagnosed prevalent cases in the US at approximately 1.5 million as of 2024, with around 755,000 of those having moderate-to-severe disease.
Crohn’s disease affects men and women roughly equally and can occur at any age, though it most commonly presents between ages 15 and 35
It is more common in individuals of White European descent, though rates among non-White populations are rising
A landmark 2023 study led by the Crohn’s & Colitis Foundation estimated that IBD overall is diagnosed in more than 0.7% of Americans — nearly 1 in 100.

Diagnosis and disease course

Diagnosis is established through endoscopy (colonoscopy and/or upper GI endoscopy), histopathology of biopsy samples, and cross-sectional imaging (MRI enterography, CT). There is no single diagnostic test — the combination of clinical presentation, endoscopic findings, and histology is required.

The disease course is highly variable. Some patients have mild, infrequent flares controlled by medication; others have chronic active disease refractory to multiple lines of treatment, leading to repeated hospitalisations, intestinal surgery, and permanent disability.

Current treatment and its limitations

Treatment of Crohn’s disease has improved substantially with the introduction of biologic agents (anti-TNF therapies like adalimumab and infliximab; anti-integrin therapies like vedolizumab; anti-IL-12/23 therapies like ustekinumab), but significant limitations remain:

A substantial proportion of patients do not achieve or maintain remission on biologics
Among Crohn’s patients initiated on biologic agents, 79.4% exhibited at least one indicator of suboptimal treatment, with associated healthcare costs rising significantly with more indicators of treatment failure.
Conventional therapies (corticosteroids, immunomodulators) carry serious long-term side effects
Many patients require surgery — roughly 70% of Crohn’s patients require at least one intestinal surgery within 10 years of diagnosis
Pain and symptom burden often persist even in patients considered to be in endoscopic remission

This treatment gap is what drives significant numbers of Crohn’s patients to explore medical cannabis for symptom management.

The Endocannabinoid System and the Gut: A Uniquely Relevant Relationship

Of all the organ systems in the body, the gastrointestinal tract is among the most richly innervated with cannabinoid receptors. The ECS is not peripheral to gut function — it is central to it, regulating intestinal motility, visceral sensation, intestinal barrier integrity, immune cell activity, and gut-brain communication.

CB1 and CB2 receptors in the gut

CB1 receptors are expressed predominantly in the enteric nervous system — the complex neural network embedded in the walls of the GI tract that regulates all aspects of gut function. CB1 is found in the submucosal and myenteric plexuses, smooth muscle, and colonic epithelium. Activation of CB1 receptors:

Reduces intestinal motility (slows transit) — directly relevant to the urgency and diarrhoea of Crohn’s
Reduces visceral hypersensitivity — dampening the pain amplification that drives abdominal cramping
Promotes gastrointestinal barrier function
Modulates nausea and vomiting through both central and peripheral mechanisms

CB1 stimulation reduces gastrointestinal inflammation in various animal models, and CB2 activation on immune cells downmodulates proinflammatory cytokine production.

CB2 receptors are expressed primarily on immune cells — including the macrophages, T lymphocytes, and dendritic cells that drive the inflammatory cascade in Crohn’s disease. CB2 activation modulates cytokine production, reduces immune cell infiltration into intestinal tissue, and promotes a shift away from pro-inflammatory signalling. CB2 is upregulated in inflamed intestinal tissue, suggesting the body’s endocannabinoid system is actively attempting to moderate the inflammatory response.

ECS dysfunction in IBD

The ECS plays an important role in modulating intestinal homeostasis, gastrointestinal motility, visceral sensation, and the immunomodulation of inflammation in IBD. Mice lacking the CB1 receptor, CB2 receptor, or both showed aggravation of inflammation in colitis models — suggesting the endocannabinoid system exerts a tonic inhibitory effect on inflammatory responses in the colon.

Research in human IBD patients has found altered ECS expression in affected gut tissue, with the degree of alteration correlating with inflammatory activity. The ECS is not simply a bystander in Crohn’s pathophysiology — it is actively engaged in the attempt to restore intestinal homeostasis, and its dysfunction may contribute to the perpetuation of inflammation.

This biological picture explains why cannabis — which activates both CB1 and CB2 receptors throughout the gut and its associated immune system — may have multiple simultaneous beneficial effects in Crohn’s disease patients: reduced pain, reduced motility, reduced visceral hypersensitivity, and modulated intestinal immune function.

The Clinical Evidence: What the Research Shows

The Naftali trial — landmark placebo-controlled study

The most cited clinical trial of cannabis in Crohn’s disease was conducted by Dr. Timna Naftali and colleagues at Meir Medical Center in Israel and published in Clinical Gastroenterology and Hepatology (2013). The study was the first placebo-controlled trial of cannabis in any form of IBD.

The double-blind, placebo-controlled study examined the effects of THC-rich cannabis in patients with active Crohn’s disease. Eight weeks of treatment with THC-rich cannabis was associated with a significant decrease of 100 points in CDAI (Crohn’s Disease Activity Index) scores. Cannabis induced clinical remission in 50% of patients, compared with 10% in the placebo group. All patients in the cannabis group expressed strong satisfaction and reported improvement in daily function.

This 50% clinical remission rate — compared with 10% for placebo — was a striking finding in a condition notoriously resistant to treatment. Importantly, however, the study did not demonstrate corresponding reductions in objective inflammatory markers (C-reactive protein, endoscopic findings), raising the important question of whether cannabis was inducing true mucosal healing or primarily improving subjective symptom experience and quality of life. This distinction remains a central unresolved question in the field.

Systematic review and meta-analysis (Vaid et al., Irish Journal of Medical Science, 2025)

A systematic review and meta-analysis published in the Irish Journal of Medical Science (2025) examined cannabis use in Crohn’s disease across randomised controlled trials. The study concluded that cannabis shows promise as a therapeutic option for Crohn’s disease, demonstrating higher remission rates and potential benefits for disease management. The review highlighted the need for larger, standardised research studies to further establish efficacy.

NORML meta-analysis summary (January 2025)

A meta-analysis covering five randomised clinical trials involving 176 participants with Crohn’s disease — summarised by NORML in January 2025 — concluded that cannabis may be “beneficial in inducing clinical remission” in Crohn’s patients, consolidating the findings of the individual trials into a consistent signal across the available RCT evidence base.

UK Medical Cannabis Registry — IBD outcomes (2025)

A 2025 analysis published examining IBD patients identified from the UK Medical Cannabis Registry (UKMCR) assessed health-related quality of life changes at 18 months after beginning cannabis-based medicinal product (CBMP) treatment. Primary outcomes included changes in the Short IBD Questionnaire (SIBDQ), EQ-5D-5L (a general quality of life measure), single-item sleep quality scale, and generalised anxiety disorder-7 (GAD-7) scale. The long-term registry data addresses a critical gap — most clinical trials in this space have been of short duration (8–12 weeks), and this analysis provides evidence of durability of benefit over 18 months.

Observational and retrospective studies

Multiple observational studies across different healthcare systems have reported consistent benefits from medical cannabis in Crohn’s patients:

Naftali et al. (original observational study, 2011): Published in Israel Medical Association Journal, this retrospective analysis of Crohn’s patients using medical cannabis found significant improvements in disease activity scores, reductions in Harvey-Bradshaw Index (a Crohn’s symptom measure), and reduced need for other medications including corticosteroids and surgery.
Retrospective review (J Clin Med, 2023): A retrospective review examining cannabis in Crohn’s and IBD patients found that cannabis may have a positive effect on disease activity, as reflected by reduction in disease activity indices and in the need for other drugs and surgical intervention.
Cochrane systematic review (Kafil et al., 2020): A Cochrane-published systematic review of cannabis and cannabinoid treatment for both Crohn’s disease and ulcerative colitis found that cannabis and cannabinoids may help with induction of remission in Crohn’s disease, though the authors called for higher-quality, adequately powered RCTs.

The critical question: symptom relief vs. mucosal healing

The most important unresolved question in the cannabis-Crohn’s evidence base is whether cannabis achieves mucosal healing — actual reduction in intestinal inflammation as measured endoscopically and by biomarkers like CRP and faecal calprotectin — or primarily improves patient-reported symptom scores and quality of life without addressing the underlying inflammatory process.

The Naftali trial (2013) showed dramatic clinical remission rates but no significant reduction in objective inflammatory markers. A subsequent trial (Naftali et al., 2017, examining CBD specifically) showed no significant clinical benefit over placebo in active Crohn’s disease.

The current evidence most consistently and reliably supports cannabis for symptom management in Crohn’s — particularly pain, diarrhoea, appetite, nausea, sleep, and quality of life — rather than for inducing or maintaining endoscopic remission. This distinction matters clinically: a patient who feels significantly better on cannabis but whose intestinal inflammation continues unchecked is at ongoing risk of disease progression, strictures, fistulas, and surgery.

This is why the medical community’s position is that cannabis should be considered as adjunctive or complementary to conventional disease-modifying treatment in Crohn’s disease, rather than as a replacement for biologics, immunomodulators, or other evidence-based therapies.

Which Symptoms Respond Best to Medical Cannabis?

Based on the cumulative clinical evidence, the Crohn’s symptoms with the strongest support for cannabinoid benefit are:

Abdominal pain: The most consistently reported benefit across clinical trials and observational studies. CB1-mediated reduction in visceral hypersensitivity and pain signal amplification directly addresses the central pain mechanism in Crohn’s.

Diarrhoea and bowel urgency: CB1 receptor activation in the enteric nervous system slows intestinal transit, reduces motility, and decreases stool frequency. Patients in clinical trials and observational studies consistently report significant reductions in diarrhoea urgency.

Nausea and appetite: Cannabis has well-established antiemetic and appetite-stimulating properties via CB1 receptor activation. These effects are particularly valuable for Crohn’s patients experiencing significant weight loss and malnutrition from disease activity and treatment side effects.

Sleep disturbance: Crohn’s patients frequently experience sleep disruption due to pain, nocturnal diarrhoea, and anxiety. Real-world registry studies report meaningful improvements in sleep quality.

Anxiety and mood: IBD has among the highest rates of comorbid anxiety and depression of any chronic GI condition. CBD’s anxiolytic properties and THC’s mood-modulating effects may contribute to overall quality of life improvement beyond direct GI effects.

Fatigue: Some patients report reduced fatigue, possibly as a secondary benefit of improved sleep and pain control, though direct evidence for cannabis specifically addressing IBD-related fatigue is limited.

Cannabinoids and Products for Crohn’s Disease

THC for symptom management

The clinical trial evidence for Crohn’s disease has primarily focused on THC-rich preparations. The Naftali (2013) trial used a THC-rich cannabis cigarette; the remission data and symptom improvements were driven by THC’s activity at CB1 and CB2 receptors throughout the gut. For patients whose primary needs are pain relief, diarrhoea reduction, and appetite improvement, THC-containing products are most directly relevant.

CBD for inflammation and tolerability

The role of CBD in Crohn’s disease is nuanced. While Naftali’s 2017 CBD-specific trial did not show significant clinical benefit over placebo on CDAI scores, preclinical research consistently shows CBD’s anti-inflammatory activity at CB2 receptors and its modulation of intestinal immune function. CBD may contribute to the anti-inflammatory benefits of whole-plant or balanced preparations, even if isolated CBD alone is insufficient for clinical remission. CBD’s tolerability profile — no psychoactive effects, lower dependency risk — also makes it attractive for daily use in a chronic condition.

Balanced THC:CBD products

Many gastroenterologists working with IBD patients who use cannabis favour balanced CBD:THC products, which may provide the anti-inflammatory and gut-calming benefits of THC combined with CBD’s anti-inflammatory and tolerability-improving properties. The 1:1 or 2:1 CBD:THC ratio is a common starting point.

Delivery method considerations

For Crohn’s disease specifically, delivery method matters clinically:

Oral tinctures and capsules: Provide longer-duration effects and more consistent dosing — appropriate for sustained symptom management. However, absorption can be variable in patients with significant small bowel involvement or post-surgical anatomy
Sublingual tinctures: Faster onset than capsules, more predictable absorption, bypassing some of the absorption variability of oral preparations
Vaporisation: Fastest onset, useful for acute flare pain or nausea. However, inhalation routes may not be appropriate for all patients
Suppositories: A delivery route with direct rectal mucosa contact that may have particular relevance for colonic Crohn’s — limited but emerging interest in this route for IBD

Dosing Considerations

Dosing for Crohn’s disease is not standardised and should be guided by a gastroenterologist or physician experienced in cannabis medicine. Key principles:

Start low, titrate gradually: Begin with 2.5–5 mg THC (equivalent) once or twice daily and increase slowly over two to four weeks
Timing relative to symptoms: Dosing before meals may help with nausea and appetite; dosing in the evening can address nocturnal pain and improve sleep
Monitor objectively: Because cannabis primarily improves subjective symptom scores in Crohn’s rather than objective inflammation markers, patients should continue regular monitoring of inflammatory markers (CRP, faecal calprotectin) and endoscopic assessment at appropriate intervals — not rely on symptom improvement alone as a measure of disease control
Do not reduce conventional therapy unilaterally: If you are on a biologic or immunomodulator, do not reduce or discontinue it because cannabis has improved your symptoms. Discuss any medication changes with your gastroenterologist

Side Effects and Drug Interactions

THC-related: Dizziness, dry mouth, increased appetite, sedation, short-term memory effects, anxiety at higher doses. For Crohn’s patients, the appetite-stimulating effect is often welcome rather than problematic
Gastrointestinal effects of cannabis: Cannabinoid hyperemesis syndrome (CHS) — a paradoxical condition of cyclical vomiting associated with heavy, chronic cannabis use — has been reported in some IBD patients. While rare, it can mimic a Crohn’s flare and should be considered if vomiting worsens with heavy cannabis use
CBD interactions: CBD is metabolised via cytochrome P450 enzymes and may interact with medications used in Crohn’s management, including some biologics and immunosuppressants. Discuss with your gastroenterologist and pharmacist
Immunosuppression considerations: Crohn’s patients on biologics or immunomodulators are already immunosuppressed. While cannabis is not an immunosuppressant in the conventional sense, the interaction between exogenous cannabinoids and immune function in this setting warrants physician oversight

Does Crohn’s Disease Qualify for a Medical Marijuana Card?

Crohn’s disease is among the most widely recognised qualifying conditions for medical marijuana programs in the United States. As of 2026, Crohn’s disease appears explicitly on the qualifying condition list in the large majority of states with active MMJ programs, reflecting both the strength of the clinical evidence and the clear unmet need in this patient population.

States that do not explicitly name Crohn’s disease typically include broader categories such as “inflammatory bowel disease,” “chronic GI conditions,” or “chronic pain” — under which Crohn’s patients can qualify.

Step-by-step qualification

Step 1: Confirm Crohn’s disease is a qualifying condition in your state. Use our state-by-state MMJ card guide to verify your state’s specific list.

Step 2: Gather your medical documentation. Collect records confirming your Crohn’s diagnosis, including endoscopy reports, biopsy results, and records of current and previous treatments. Documentation of inadequate response to conventional therapy — particularly relevant if you have been through multiple biologics — supports your case significantly.

Step 3: Schedule a telehealth MMJ consultation. Services such as NuggMD, Leafwell, and Veriheal provide video consultations with state-licensed MMJ physicians. The appointment typically takes 15–20 minutes. Bring your GI records and be prepared to describe your primary symptoms, their severity, and their impact on daily life and work.

Step 4: Receive your recommendation and register if required. Your physician will issue a written recommendation upon approval. Some states require registration with a state patient registry before dispensary access.

Step 5: Keep your gastroenterologist involved. While your MMJ card can be obtained independently, informing your gastroenterologist about your intention to use medical cannabis is important — particularly regarding drug interactions with biologics and immunomodulators, and to ensure your inflammatory disease activity continues to be monitored appropriately with objective measures.

Frequently Asked Questions

Can cannabis cure Crohn’s disease? No. There is no evidence that cannabis cures Crohn’s disease or permanently alters its underlying pathophysiology. Clinical trial evidence most consistently supports cannabis as a tool for symptom management — particularly pain, diarrhoea, appetite, and quality of life — rather than as a disease-modifying agent that achieves mucosal healing.

If cannabis puts me in remission, can I stop my biologic? No — not without consulting your gastroenterologist. Clinical remission (feeling better) and endoscopic remission (mucosal healing confirmed by colonoscopy and inflammatory biomarkers) are different endpoints. Cannabis may achieve the former without the latter. Stopping a biologic that is controlling your intestinal inflammation — even when you feel well — carries real risks of disease flare and progression. Any changes to your disease-modifying therapy should be made by your gastroenterologist based on objective disease assessments, not symptom scores alone.

Is smoking cannabis appropriate for Crohn’s disease? Smoking is generally not recommended. Combustion products have independent negative effects on gastrointestinal health and on gut microbiome composition. Vaporisation, oral tinctures, and capsules are preferred delivery routes for Crohn’s patients.

Does cannabis interact with my biologic or immunomodulator? Potential interactions exist. CBD in particular can affect the metabolism of certain medications via cytochrome P450 enzyme pathways. Always discuss your full medication list with your gastroenterologist and pharmacist before beginning cannabis treatment.

What about cannabis use in Crohn’s patients who have had intestinal surgery? Post-surgical anatomy — including resections, strictureplasties, or ostomies — can affect the absorption of oral cannabis preparations. Patients with significant small bowel resections may have altered absorption of oil-based preparations. Sublingual or inhaled delivery routes may provide more predictable absorption in this population. Discuss with your physician.

Key Takeaways

Crohn’s disease affects approximately 1–1.5 million Americans, with around half having moderate-to-severe disease, and significant unmet need despite advances in biologic therapies
The ECS is deeply integrated into gut function — regulating motility, visceral pain, immune activity, and intestinal barrier integrity — making it a biologically compelling target in Crohn’s disease
Clinical trial evidence shows cannabis — particularly THC-rich preparations — can induce clinical remission in approximately 50% of active Crohn’s patients and consistently improves pain, diarrhoea, appetite, sleep, and quality of life
The critical caveat: current evidence most reliably supports symptom improvement rather than mucosal healing; cannabis should be adjunctive to, not a replacement for, evidence-based disease-modifying therapy
Crohn’s disease qualifies for medical marijuana in the large majority of US states with active MMJ programs
Patients should keep their gastroenterologist involved in cannabis treatment decisions and continue objective disease monitoring even when symptoms improve

Sources and Further Reading

Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., & Konikoff, F.M. (2013). Cannabis Induces a Clinical Response in Patients With Crohn’s Disease: A Prospective Placebo-Controlled Study. Clinical Gastroenterology and Hepatology, 11(10), 1276–1280. https://doi.org/10.1016/s1542-3565(13)00604-6
Vaid, R., Fareed, A., Qader, R., et al. (2025). Cannabis use in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials. Irish Journal of Medical Science, 194(2), 439–446. https://doi.org/10.1007/s11845-024-03844-w
UK Medical Cannabis Registry — IBD analysis (2025). An updated analysis of clinical outcomes of cannabis-based medicinal products for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. https://doi.org/10.1080/17474124.2024.2443574
Kafil, T.S., Nguyen, T.M., MacDonald, J.K., & Chande, N. (2020). Cannabis for the Treatment of Crohn’s Disease and Ulcerative Colitis: Evidence From Cochrane Reviews. Inflammatory Bowel Diseases, 26(4), 502–509. https://doi.org/10.1093/ibd/izz233
Naftali, T., Mechulam, R., Marii, A., et al. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial. Digestive Diseases and Sciences, 62(6), 1615–1620. https://doi.org/10.1007/s10620-017-4540-z
PMC (2022). Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease — A Systematic Review. Frontiers in Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC8727741/
Mucosal Immunology / Nature. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. https://www.nature.com/articles/mi201118
Lewis, J.D., Parlett, L.E., Jonsson Funk, M.L., et al. (2023). Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology. [Crohn’s & Colitis Foundation landmark study]. https://www.crohnscolitisfoundation.org/groundbreaking-study
Pilon, D., Ding, Z., Muser, E., et al. (2022). Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease. Crohn’s & Colitis 360, otac021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9802278/
NORML (January 2025). Meta-Analysis: Cannabis May Be “Beneficial in Inducing Clinical Remission” in Patients With Crohn’s Disease. https://norml.org/news/2025/01/30/meta-analysis-cannabis-may-be-beneficial-in-inducing-clinical-remission-in-patients-with-crohns-disease/
Scott, C., Hall, S., Zhou, J., & Lehmann, C. (2023). Treatment of Crohn’s disease with cannabis: an observational study. Journal of Clinical Medicine, 13(1), 227. https://doi.org/10.3390/jcm13010227
Journal of Crohn’s and Colitis / Oxford Academic. Cannabis, Cannabinoids, and the Endocannabinoid System — Is there Therapeutic Potential for Inflammatory Bowel Disease? https://academic.oup.com/ecco-jcc/article/13/4/525/5173479

This article was written and medically reviewed in March 2026. It will be updated as new research becomes available. For state-specific qualifying condition information, see our How to Get Your MMJ Card guide.